Duchenne Muscular Dystrophy (DMD) Clinical Trial
Official title:
Open, Randomized, 3 Period Cross-over Design, in Healthy Volunteers to Compare the Pharmacokinetics Profiles of 3 Treatments: ISO 20, IBU 200 and IBU Plus ISO Combinations (200 + 20) Administered Per os as Single Doses
This study will evaluate the pharmacokinetics plasma profile of 3 treatments: ISO 20, IBU 200
and IBU and ISO combinations (200 +20) given in single dose.
This study is being conducted to support the submission for new indication in treatment of
the combinations of Isosorbide Dinitrate and Ibuprofen as a treatment for Duchenne muscular
dystrophy.
This trial is designed to define drug interactions following the combined administration of
Isosorbide Dinitrate, a NO donor, and ibuprofen, NSAID, a through pharmacokinetics approach.
Both ibuprofen and Isosorbide Dinitrate were licensed worldwide. Ibuprofen is approved for
use in adults and children; Isosorbide is approved for use in adults. Ibuprofen is currently
used in pediatric patients as a first line anti-inflammatory and antipyretic agent. Consensus
exists that among NSAIDs ibuprofen is the one endowed with less adverse effects (see note 66
of the Italian Drug Agency AIFA and MEA). No specific studies concerning safety and
tolerability of ISDN in pediatric patients have been reported.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02814019 -
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
|
Phase 3 | |
| Completed |
NCT00654784 -
Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Recruiting |
NCT02614820 -
The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD
|
N/A | |
| Withdrawn |
NCT02036463 -
A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT02255552 -
Study of Eteplirsen in DMD Patients
|
Phase 3 | |
| Not yet recruiting |
NCT06392724 -
A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.
|
Early Phase 1 | |
| Completed |
NCT01982695 -
Cardiomyopathy in DMD: Lisinopril vs. Losartan
|
N/A | |
| Recruiting |
NCT05516745 -
E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"
|
N/A | |
| Completed |
NCT02420379 -
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
|
Phase 2 | |
| Active, not recruiting |
NCT05135663 -
Extension Study of NS-089/NCNP-02 in DMD
|
Phase 2 | |
| Completed |
NCT01380964 -
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
|
N/A | |
| Completed |
NCT05990608 -
Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
|
||
| Recruiting |
NCT04322357 -
Twice Weekly Steroids and Exercise as Therapy for DMD
|
Phase 2 | |
| Completed |
NCT01540409 -
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Terminated |
NCT04184882 -
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 1 | |
| Terminated |
NCT04254172 -
A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
|
||
| Recruiting |
NCT05524883 -
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
|
Phase 1/Phase 2 | |
| Completed |
NCT01761292 -
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
|
Phase 1/Phase 2 |